RCM
BDTX icon

RA Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

RA Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,525,754
Closed -$17.9M – 79
2024
Q1 		$17.9M Hold
3,525,754
– – 0.23% 67
2023
Q4 		$9.91M Hold
3,525,754
– – 0.15% 56
2023
Q3 		$10.1M Hold
3,525,754
– – 0.2% 55
2023
Q2 		$17.8M Buy
3,525,754
+935,850
+36% +$1.91M 0.34% 47
2023
Q1 		$4.89M Hold
2,589,904
– – 0.11% 54
2022
Q4 		$4.66M Hold
2,589,904
– – 0.09% 61
2022
Q3 		$4.38M Hold
2,589,904
– – 0.09% 73
2022
Q2 		$6.37M Hold
2,589,904
– – 0.17% 66
2022
Q1 		$7.17M Hold
2,589,904
– – 0.16% 83
2021
Q4 		$13.8M Hold
2,589,904
– – 0.24% 69
2021
Q3 		$21.9M Hold
2,589,904
– – 0.3% 61
2021
Q2 		$31.6M Hold
2,589,904
– – 0.51% 54
2021
Q1 		$62.8M Hold
2,589,904
– – 0.95% 34
2020
Q4 		$83M Hold
2,589,904
– – 1.16% 26
2020
Q3 		$78.3M Hold
2,589,904
– – 1.43% 23
2020
Q2 		$109M Hold
2,589,904
– – 2.13% 16
2020
Q1 		$64.6M Buy
+2,589,904
New +$78.8M 2.04% 19

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RA Capital Management's BDTX Position: Q2 2024 in Review

RA Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2024, closing a stake of 3,525,754 shares — an estimated $17.9M sold.

RA Capital Management first reported a position in BDTX in Q1 2020 and held it in 17 quarters. The position peaked at $109M in Q2 2020. 90 funds tracked by Wall St. Rank hold BDTX as of Q2 2024.

  • RA Capital Management reported no remaining Black Diamond Therapeutics position as of Q2 2024 after selling out during the quarter.
  • RA Capital Management sold 3,525,754 Black Diamond Therapeutics shares in Q2 2024, an estimated $17.9M.
  • RA Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 17 quarters.
  • RA Capital Management's Black Diamond Therapeutics position peaked at $109M in Q2 2020.
  • 90 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2024.

Based on RA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.